新型Atellica IM高敏前列腺特异抗原检测的分析验证与对比评估
本研究用236份血清样本评估新开发的Atellica IM高敏PSA检测的分析与临床性能,并与四种FDA批准的PSA检测对比。结果显示该检测灵敏度高(LOD 0.01 μg/L),与Cobas和Hybritech一致性良好,在4 μg/L阈值下诊断灵敏度98%、特异度35%。
要点
- hsPSA Atellica检测LOD为0.01 μg/L,LOQ为0.028 μg/L(CV 3.2%,准确度115%)。
- 在4 μg/L临床决策阈值下诊断灵敏度98%、特异度35%。
- 3–10 μg/L区间87份样本与Hybritech一致性达96.6%(κ=0.82)。
核心结论
- hsPSA Atellica检测具有出色的分析灵敏度,与现有检测方法高度一致,支持其在前列腺癌诊断和随访中的临床效用。
研究设计与样本
- 研究分析了236份来自健康个体及有无前列腺癌患者的血清样本,使用hsPSA Atellica检测和四种FDA批准的PSA检测(Hybritech Access、Architect、Atellica、Cobas)进行对比。
主要发现
- hsPSA Atellica检测的LOD为0.01 μg/L,LOQ为0.028 μg/L(CV 3.2%,准确度115%)。
- 低、中、高PSA水平的CV分别为4.2%、3.8%、2.4%。
- 与Cobas和Hybritech PSA检测一致性尤其强。
- 在4 μg/L临床决策阈值下诊断灵敏度98%、特异度35%。
- 在3–10 μg/L的87份样本中,与Hybritech一致性达96.6%(κ=0.82);检测在PSA浓度高达13,311 μg/L时仍准确,钩状效应极小。
临床怎么用
- 该检测可用于前列腺癌的诊断和随访,尤其在低浓度区间表现良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite standardization efforts, significant inter-assay variability persists among prostate-specific antigen (PSA) tests, impacting prostate cancer (PCa) diagnosis and monitoring. We aimed to evaluate the analytical and clinical performance of the newly developed Atellica IM high-sensitivity PSA (hsPSA Atellica) assay compared with established PSA assays. METHODS: A total of 236 serum samples from healthy individuals and patients with or without PCa were analyzed using the hsPSA Atellica assay and four FDA-approved PSA assays: Hybritech Access, Architect, Atellica, and Cobas. Analytical performance included limit of detection (LOD), limit of quantification (LOQ), linearity, inter-assay precision, and hook effect. Method comparison was performed using Passing-Bablok regression, Bland-Altman analysis, and kappa index concordance. RESULTS: The hsPSA Atellica assay demonstrated a LOD of 0.01 μg/L and LOQ of 0.028 μg/L (CV: 3.2 %, accuracy: 115 %). Precision was maintained across concentrations, with CVs of 4.2 %, 3.8 %, and 2.4 % at low, medium, and high levels of PSA. Strong agreement was observed with the compared tests, particularly with Cobas and Hybritech PSA assays. Diagnostic sensitivity and specificity at the 4 μg/L clinical decision threshold were 98 % and 35 %, respectively. In 87 samples between 3 and 10 μg/L, concordance between hsPSA Atellica and Hybritech reached 96.6 % (κ=0.82). The assay remained accurate up to PSA concentrations of 13,311 μg/L, showing minimal hook effect. CONCLUSIONS: The hsPSA Atellica assay shows excellent analytical sensitivity and strong agreement with established assays. To our knowledge, this is the first published evaluation of this assay, supporting its clinical utility in both PCa diagnosis and follow-up.
引用
- Filella X, González-Escribano C, Rodríguez-García M, et al. Analytical verification and comparative assessment of the new Atellica IM high-sensitivity prostate specific antigen assay. Clin Chem Lab Med. 2025. PMID: 41427577. doi:10.1515/cclm-2025-1431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。